|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
94,670,000 |
Market
Cap: |
98.46(M) |
Last
Volume: |
940,193 |
Avg
Vol: |
715,711 |
52
Week Range: |
$0.754 - $7.3 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Assertio Therapeutics is a pharmaceutical company. Co.'s primary marketed products include: INDOCIN® (indomethacin) Suppositories and INDOCIN® (indomethacin) Oral Suspension, which is a suppository form and oral solution of indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), approved for moderate to severe rheumatoid arthritis, ankylosing spondylitis and osteoarthritis; CAMBIA® (diclofenac potassium for oral solution), which is a prescription NSAID indicated for the acute treatment of migraine attacks in adults; and Otrexup® (methotrexate) injection, used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Moretti August J |
Chief Financial Officer & SVP |
|
2017-04-02 |
4 |
D |
$12.55 |
$11,797 |
D/D |
(940) |
41,785 |
|
- |
|
Vargas Thadd M |
Senior VP, BD |
|
2017-04-02 |
4 |
D |
$12.55 |
$11,797 |
D/D |
(940) |
91,567 |
|
- |
|
Staple Peter D |
Director |
|
2017-03-31 |
4 |
OE |
$3.27 |
$49,050 |
I/I |
15,000 |
99,403 |
|
- |
|
Higgins Arthur J |
President and CEOOfficer |
|
2017-03-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,000 |
|
- |
|
Molinelli Gavin |
Director |
|
2017-03-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,295,270 |
|
- |
|
Zenoff David B |
Director |
|
2017-02-21 |
4 |
OE |
$1.49 |
$212,900 |
I/I |
70,000 |
93,999 |
|
- |
|
Schoeneck James A |
President and CEO |
|
2016-12-23 |
4 |
GA |
$0.00 |
$0 |
I/I |
61,207 |
495,105 |
|
- |
|
Schoeneck James A |
President and CEO |
|
2016-12-23 |
4 |
GD |
$0.00 |
$0 |
D/D |
61,207 |
0 |
|
- |
|
Schoeneck James A |
President and CEO |
|
2016-12-01 |
4 |
D |
$18.55 |
$1,239,010 |
D/D |
(66,793) |
61,207 |
|
- |
|
Srinivas Rao |
SVP and Chief Medical Officer |
|
2016-12-01 |
4 |
D |
$18.55 |
$88,910 |
D/D |
(4,793) |
17,967 |
|
- |
|
Moretti August J |
Chief Financial Officer & SVP |
|
2016-12-01 |
4 |
D |
$18.55 |
$201,323 |
D/D |
(10,853) |
40,225 |
|
- |
|
Gosling Matthew M |
SVP, General Counsel |
|
2016-12-01 |
4 |
D |
$18.55 |
$244,897 |
D/D |
(13,202) |
78,317 |
|
- |
|
Vargas Thadd M |
Senior VP, BD |
|
2016-12-01 |
4 |
D |
$18.55 |
$186,502 |
D/D |
(10,054) |
90,007 |
|
- |
|
Moretti August J |
Chief Financial Officer & SVP |
|
2016-11-14 |
4 |
AS |
$20.84 |
$104,200 |
D/D |
(5,000) |
21,680 |
|
- |
|
Moretti August J |
Chief Financial Officer & SVP |
|
2016-11-14 |
4 |
OE |
$12.69 |
$63,450 |
D/D |
5,000 |
26,680 |
|
- |
|
Fogarty James P |
Director |
|
2016-10-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
16,450 |
|
- |
|
Schoeneck James A |
President and CEO |
|
2016-10-12 |
5 |
GD |
$0.00 |
$0 |
I/I |
2,000 |
495,105 |
|
- |
|
Vargas Thadd M |
Senior VP, BD |
|
2016-09-21 |
4 |
AS |
$25.00 |
$281,250 |
D/D |
(11,250) |
73,086 |
|
- |
|
Moretti August J |
Chief Financial Officer & SVP |
|
2016-08-10 |
4 |
AS |
$21.40 |
$107,000 |
D/D |
(5,000) |
21,680 |
|
- |
|
Moretti August J |
Chief Financial Officer & SVP |
|
2016-08-10 |
4 |
OE |
$12.69 |
$41,839 |
D/D |
3,297 |
24,977 |
|
- |
|
Vargas Thadd M |
Senior VP, BD |
|
2016-08-10 |
4 |
AS |
$20.92 |
$549,987 |
D/D |
(26,290) |
84,336 |
|
- |
|
Schoeneck James A |
President and CEO |
|
2016-06-06 |
4 |
GA |
$0.00 |
$0 |
I/I |
38,163 |
435,898 |
|
- |
|
Schoeneck James A |
President and CEO |
|
2016-06-06 |
4 |
GD |
$0.00 |
$0 |
D/D |
38,163 |
0 |
|
- |
|
Vargas Thadd M |
Senior VP, BD |
|
2016-05-23 |
4 |
AS |
$20.00 |
$300,000 |
D/D |
(15,000) |
109,297 |
|
- |
|
Schoeneck James A |
President and CEO |
|
2016-05-18 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,000 |
397,735 |
|
- |
|
165 Records found
|
|
Page 4 of 7 |
|
|